Skip to main content
Download PDF

Ubiquitin-conjugating enzyme UBE2J1 negatively modulates interferon pathway and promotes RNA virus infection

Virology Journal volume 15, Article number: 132 (2018) Cite this article

Abstract

Background

Viral infection activates innate immune pathways and interferons (IFNs) play a pivotal role in the outcome of a viral infection. Ubiquitin modifications of host and viral proteins significantly influence the progress of virus infection. Ubiquitin-conjugating enzyme E2s (UBE2) have the capacity to determine ubiquitin chain topology and emerge as key mediators of chain assembly.

Methods

In this study, we screened the functions of 34 E2 genes using an RNAi library during Dengue virus (DENV) infection. RNAi and gene overexpression approaches were used to study the gene function in viral infection and interferon signaling.

Results

We found that silencing UBE2J1 significantly impaired DENV infection, while overexpression of UBE2J1 enhanced DENV infection. Further studies suggested that type I IFN expression was significantly increased in UBE2J1 silenced cells and decreased in UBE2J1 overexpressed cells. Reporter assay suggested that overexpression of UBE2J1 dramatically suppressed RIG-I directed IFNβ promoter activation. Finally, we have confirmed that UBE2J1 can facilitate the ubiquitination and degradation of transcription factor IFN regulatory factor 3 (IRF3).

Conclusion

These results suggest that UBE2 family member UBE2J1 can negatively regulate type I IFN expression, thereby promote RNA virus infection.

Background

Dengue virus (DENV), transmitted by Aedes aegypti and Aedes albopicuts, causes an emerging tropical disease that arouses increasing public concern in recent years [1, 2]. Up to 1.5 million infected individuals present with clinical symptoms and ~ 500,000 infections progress to the life-threatening dengue hemorrhagic fever and dengue shock syndrome. No specific treatment for dengue infection is available at the moment.

Viral infection activates innate sensing pathways. Interferons (IFNs) play a pivotal role in the outcome of a viral infection, and regulate both innate and adaptive antiviral responses [3]. IFN-α/β regulates the synthesis of antiviral proteins and immunoregulatory factors through the JAK/STAT signaling pathway [4, 5]. A lot of host and viral proteins can regulate the type I interferon pathway thereby significantly influence the progress of virus infection.

Ubiquitin modifications of proteins within the signaling cascades induce type I interferon expression, and in contrast, some viruses are found to utilize the ubiquitin system to suppress IFNs [6, 7]. Among them, classical K48-linked polyubiquitin chains mediate the target proteins for proteasomal degradation, while K63-linked polyubiquitination usually stabilize the target proteins and further activate their function. K48-linked polyubiquitin chains ligated the CARD domain of RIG-I and MDA5, leading to proteasome-mediated degradation of both receptors and repressing IFN-I signaling [8]. In contrast, K63-linked ubiquitination positively regulates signal transduction events and does not induce protein degradation [9]. In addition to RIG-I, TRAF3/IKKε/IRF3/7 in the type I interferon signaling pathway and NEMO/IKKα/RIP1 in the NF-κB signaling pathway have also been reported to be regulated by different types of ubiquitination [10, 11].

Ubiquitination is catalyzed by a series of ubiquitin related enzymes, which are the ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin protein ligase (E3) and deubiquitinating enzymes (Dubs). Generally, the E3 determined the substrate specificity, while the E2s have the capacity to determine ubiquitin chain topology and emerged as key mediators of chain assembly [9].

E2 enzymes direct the ubiquitination process to distinct subsets of ubiquitin lysines. Different E2 enzymes influence distinct types of ubiquitin linkages. For example, the E2 enzyme UBE2N (also known as Ubc13) heterodimerizes with UBE2V1, and mediates K63-linked ubiquitination [12, 13]. UBE2L3 promotes K48-ubiquitylation of pro-IL-1β and dampens mature-IL-1β production [14]. Cdc34 had a strong preference for K48, with lower selectivity towards K11 and K63 [15]. UBE2F, combined with SAG/CUL5 complex, activates CRL5 (Cullin-RING-ligase-5) and ubiquitylates NOXA via a novel K11 linkage which leads to proteasomal degradation [16]. In addition to ubiquitination, some other E2s could mediate ubiquitin-like protein modification. Ubc9 (UBE2I) is the central enzyme in SUMO conjugation system. It forms a SUMO~Ubc9 thioester bond then transfer SUMO to a target protein substrate in the presence of an E3 [17]. In a mechanism similar to ubiquitination, ISG15 is conjugated to targets via the sequential co-operation of E1, E2 and E3 enzymes, in which the specific E2 was UBE2L6 [18].

There are around 40 ubiquitin E2 family genes in human genome, and a lot of them are associated with pathologies and diseases [9]. Since E2s plays important roles in determining the topology of ubiquitin chains and the fates of the proteins modified, we screened 34 UBE2 genes using an RNAi library and investigated the potential role of individual E2 during DENV infection. Here, we reported UBE2J1 as a negative regulator of IFN pathway by mediating IRF3 ubiquitination and degradation.

Methods

Virus, cell culture and infection

DENV-2 virus (DENV New Guinea C stain) and Zika virus (ZIKV, MR766 strain) were propagated in mosquito C6/36 cells (ATCC® CRL-1660). Influenza A virus (H1N1-A/PR/8/34) and Sendai virus (SeV) was propagated in 10 days old embryonated chicken eggs (Bejing Laboratory Animal Research Center, Beijing, China), and titrated by hemagglutination assay using chicken red blood cells (BeNa Culture Collection, Bejing, China).

Human epithelial cell line HEK293T cells, A549 cells, and human Peripheral Blood Mononuclear Cells (PBMCs) were cultured in DMEM or RPMI 1640 medium supplemented with fetal bovine serum (10%) and penicillin/streptomycin (1%). HEK293T cells were infected with DENV, ZIKV, SeV or H1N1 at a multiplicity of infection (MOI) of 1, unless otherwise stated.

Plasmid constructs

Recombinant plasmid for UBE2J1 expression was constructed using standard protocols by inserting the UBE2J1 open reading frame into the pcDNA3.1 vector. Expression plasmids for the active caspase recruitment domain (CARD) containing form of RIG-I (RIG-I-N), MAVS, TBK1, IKKε and the constitutively active IRF3 (IRF3-5D), Luciferase reporter plasmids IFNβ-Luc and IRF3-Luc were kindly provided by Dr. Rongtuan Lin, McGill University, Canada [19].

RNAi and transfections

HEK293T cells (~ 5 × 105) were transfected with 500 ng of plasmid DNA or si/shRNA using Lipofectamine 2000 (Invitrogen, USA) according to the manual of the manufacturer. 24 h post transfection, the cells were infected with DENV at an MOI of 1 for another 48 h (unless otherwise stated). The UBE2s siRNA library for 34 genes was purchased from RiboBio Co., China. The shRNA sequences for human UBE2J1 gene were 5’-GTGAAGAGTCCGGCTGTTA-3′, and 5’-TAACAGCCGGACTCTTCAC-3′. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to confirm the RNAi efficiency of specific gene.

RNA isolation and qRT-PCR

Total RNA were extracted using the total RNA kit (OMEGA, USA) and reverse-transcribed using the PrimeScriptTM Master Mix kit (TaKaRa, Japan). The intracellular viral loads, in terms of transcript levels of the specific viral genes, were quantified through qRT-PCR and normalized to β-actin gene. (Oligo-primer sequences for qRT-PCR of this study were shown in “Additional file 1”).

TCID50 assay and viral growth kinetics

The cell-free supernatants were collected and the titers of DENV and ZIKV were determined with a median tissue culture infective dose (TCID50) assay according to standard protocols on Vero cells [20, 21]. Briefly, samples were serially diluted and inoculated into Vero cells in 96-well plates. After 5-day incubation, cells were examined for cytopathic effects (CPE) under a light microscope. The virus titer (TCID50/ml) was calculated using the Reed-Muench method. The titers of H1N1 and SeV were measured by hemagglutination assay using the chicken red blood cells [22].

Luciferase reporter assays

Luciferase reporter assays were performed as described previously [23]. Briefly, 70% confluent HEK293T cells were transfected with 10 ng of pRL-TK reporter (Renilla luciferase, internal control), 100 ng of IFNβ luciferase reporter (firefly luciferase, experimental reporter), 50 ng of IFNβ activators (RIG-I-N, MAVS, TRAF3, TBK1, IKKε, or IRF3-5D), as well as either 100 ng of recombinant over-expressing or shRNAs plasmids (Vector, UBE2J1, scramble shRNAs or UBE2J1 shRNA). For measuring the activation of transcription factor IRF3, HEK293T cells were transfected with IRF3 specific luciferase reporter pIRF3-Luc (pRD (III–I)-Luc) plasmid instead of the IFNβ luciferase reporter. At 24 h post-transfection, luciferase activity was measured using a Promega Dual Glow kit according to the instructions of the manufacturer.

Western blot

HEK293T cells (~ 5 × 106) were transfected with UBE2J1 overexpressing or silencing plasmids and then infected with DENV. At indicated time points post-infection, cell lysates were subjected to SDS-PAGE and transferred onto a PVDF membrane for western blotting. The following antibodies were used for western blotting: anti-human GAPDH polyclone antibody (Proteintech, USA), His-tag polyclone antibody (GenScript, USA), HA-probe mouse monoclonal antibody (Santa Cruz, USA), anti-Flag-tag (Sigma-Aldrich, USA), RIG-I pathway antibody sampler kit (Cell Signaling Technology, USA), IRF3 polyclonal antibody (Biolegend, USA), HRP-conjugated donkey anti-rabbit IgG and rabbit anti mouse IgG mAb (Biolegend, USA). The signals were detected using an Enhanced Chemiluminescent (ECL) kit according to the manufacturer’s instructions (Merck Millipore Ltd., USA).

Enzyme linked immunosorbent assay (ELISA)

HEK293T Cells were transfected with UBE2J1 overexpressing or silencing plasmids and then infected with DENV. At indicated time points post-infection, IFNβ protein in the cell supernatant were determined by ELISA kit (PBL Assay Science, USA) according to the manufacturer’s instructions. .

Ubiquitination and Coimmunoprecipitation assays

HEK293T cells (~ 5 × 106) were transfected with Flag-IRF3, His-UBE2J1 (or vector), together with HA-ubiquitin, HA-K48 ubiquitin or HA-K63 ubiquitin plasmids (Addgene, USA), respectively. 48 h later, cells were treated with proteasome inhibitor MG132 (20 μM, Sigma-Aldrich, USA) for another 6 h before harvest.

Immunoprecipitation were performed with anti-Flag® M2 Affinity Gel (Sigma-Aldrich, USA) according to the manufacturer’s instructions. Briefly, 500 μl of cell lysates were incubated with 100 μl of the anti-Flag M2 Affinity Gel overnight at 4 °C. The beads were washed four times with 1 ml of lysis buffer containing 500 mM NaCl. The immunoprecipitated Flag-IRF3 proteins were then eluted and subjected to western blots. The co-immunoprecipitated UBE2J1 and ubiquitination signal on Flag-IRF3 was detected using anti-His and anti-HA antibodies, respectively.

Statistical analysis

Statistical significances were calculated with an unpaired two tailed Student’s t-test using Prism 6 software (GraphPad).

Results

Roles of UBE2 family during DENV infection

RNAi screening of 34 human UBE2 genes were performed on HEK293T cells to investigate which UBE2s are involved in DENV replication. The DENV viral replications were analyzed by measuring the copies of viral mRNA transcripts (Envelope (E) gene) though qRT-PCR in each UBE2 siRNA treated HEK293T cells at 48 h post infection. Among them, DENV replication were significantly decreased in CDC34, UBE2B and UBE2J1 siRNA-treated cells, while increased in UBE2S, UBE2U, UBE2V1 and UBE2I siRNA-treated cells (t-test, p < 0.05 Vs NC) (Fig. 1a). Since UBE2J1 silencing caused a most dramatic decrease on DENV replication, we focused on the role of UBE2J1 on DENV infection in this study.

Fig. 1
figure 1

UBE2J1 is involved in DENV infection. a RNAi screening of UBE2 family during DENV infection: HEK293T cells were transfected with siRNAs for each specific gene of UBE2 family, and infected with DENV for 48 h at an MOI = 1. The viral loads were analyzed by measuring the DENV E gene copy using qRT-PCR and normalized to a human β-actin gene. The relative replication level of DENV in nonsense siRNA (N.C.) transfected cells was set to 1. The red lines were set to mark the significant suppression (fold change < 0.5) or stimulation (fold change > 1.5) of DENV RNA replication. Results were expressed as the mean + SD. Each siRNA treatment was compared to N.C. group individually: * p < 0.05 and ** p < 0.01 (t-test). b The qRT-PCR analysis of UBE2J1 mRNA expression in A549, PBMCs, and HEK293T before and after DENV infection. Results were expressed as the mean + SD. * p < 0.05 and ** p < 0.01 (t-test). (C) Immunoblots analysis of UBE2J1 expression in HEK293T cells before and after DENV infection. The relative grey density of immunoblots bands (UBE2J1/β-actin) was analyzed by ImageJ software. Representative results from at least 3 independent experiments

Full size image

UBE2J1 is upregulated during DENV infection

By using qRT-PCR, we noted an increased UBE2J1 mRNA expression in DENV stimulated human A549, PBMCs, and HEK293T cells (Fig. 1b). Consistently, the protein level of UBE2J1 was also induced in HEK293T cells after DENV infection (Fig. 1c). These data suggest that UBE2J1 may involve in DENV infection of these cells.

UBE2J1 promotes RNA virus replication

To confirm the role of endogenous UBE2J1 in DENV infection, UBE2J1 expression was silenced using RNAi approach. shRNA specifically targeting UBE2J1 significantly suppressed UBE2J1 mRNA expression compared with cells receiving scramble shRNA (N.C.) (Fig. 2a). Cell viability was not influenced during RNAi and DENV infection process (Fig. 2b) (DENV does not cause cytopathic effect in HEK293T cells). The viral replication efficiency, in terms of the mRNA copies the DENV E gene, decreased by 1.3-fold, 3.2-fold and 3.4-fold (p < 0.05) in UBE2J1-silenced cells compared with control cells at 12, 24 and 48 h post DENV infection, respectively (Fig. 2c). The protein levels of DENV E gene were also decreased in UBE2J1 silenced cells compared with controls at indicated time points post-infection (Fig. 2c). Conversely, we noted a significant increase in viral loads (~ 3 fold) in UBE2J1 overexpressed HEK293T cells (Fig. 2d). Meanwhile, the titers of DENV in cell supernatants, as determined by TCID50 assay, were significantly decreased in UBE2J1 silenced cells (Fig. 2e) and increased in UBE2J1 overexpressed cells (Fig. 2f). Similar results were obtained in DENV infected K562 cells (Fig. 2g and h), which suggesting that UBE2J1 also involved in DENV infection of immune cells. Overall, these data suggest that UBE2J1 could promote DENV replication.

Fig. 2
figure 2

UBE2J1 promotes DENV infection. a RNAi efficiency of UBE2J1 shRNA in HEK293T cells. b Silencing UBE2J1 by RNAi and infecting cell with DENV for 24 h or 48 h (MOI of 1) showed no cytotoxic effect to HEK293T cells (Cell Viability assay, Promega). c DENV viral loads in UBE2J1 shRNA (or scramble shRNA, N.C.) treated HEK293T cells at 12 h, 24 h, and 48 h post DENV infection (MOI of 1). The viral burdens were analyzed by measuring the virus E gene expression using qRT-PCR and western blot, and normalized to human β-actin or GAPDH, respectively. d qRT-PCR and western blot analysis of DENV E gene expression in HEK293T cells with or without UBE2J1 overexpression at 12 h, 24 h, and 48 h post DENV infection. e and f Viral titers in supernatants of DENV infected HEK293T cells determined by TCID50 assay on Vero cells. g-h qRT-PCR analysis of viral mRNAs and TCID50 assay of viral titers in K562 cells transfected with UBE2J1 shRNA or UBE2J1 overexpression plasmids post DENV infection. Results were expressed as the mean + SD. * p < 0.05 and ** p < 0.01 (t-test). Representative results from at least 3 independent experiments

Full size image

Besides of this, UBE2J1 was found to promote replication of other viruses, including Zika virus (ZIKV), Influenza virus (H1N1) and Sendai virus (SeV) (Fig. 3). Viral mRNA copies and virus titers of ZIKV (Fig. 3a and b), H1N1 (Fig. 3c and d) and SeV (Fig. 3e and f) were significantly lower in UBE2J1 silenced cells while higher in UBE2J1 overexpressed cells, when comparing with controls. Interestingly, all these tested viruses are single-stranded RNA virus.

Fig. 3
figure 3

UBE2J1 promotes ZIKV, H1N1 and SeV infection. a-f viral mRNA copies and viral titers of ZIKV (a and b), H1N1 (c and d) and SeV in (e and f) in UBE2J1 silenced (a, c, and e) or overexpressed (b, d, and f) HEK293T cells compared with controls. HEK293T cells were transfected with UBE2J1 shRNA or UBE2J1 overexpression plasmids for 24 h, and then infected with ZIKV (MOI of 1 for 24 h), H1N1 (MOI of 1 for 24 h) or SeV (MOI of 1 for 16 h), respectively. The intracellular viral loads, in terms of transcript levels of the specific viral genes (Additional file 1: Table S1), were quantified through qRT-PCR and normalized to β-actin gene. The viral titers were determined by TCID50 assay (for ZIKV) or hemagglutination assay (for H1N1 and SeV, HA units (HAU) /ml). Results were expressed as the mean + SD. * p < 0.05 and ** p < 0.01 (t-test). Representative results from at least 3 independent experiments

Full size image

UBE2J1 negatively regulates virus-induced IFNβ production

Ubiquitination is reported as regulators of antiviral innate responses including the interferon signaling pathway. The aforementioned results clearly demonstrate a pro-vial role of UBE2J1 for several RNA viruses. We next evaluated whether UBE2J1 influence the innate immune responses to viral infection. The expression of IFNβ mRNA and protein were significantly increased at 24 h and 48 h post DENV infection in UBE2J1 silenced cells (Fig. 4a and b). Consistently, UBE2J1 silencing also enhanced the RIG-I directed IFNβ promoter-driven luciferase (IFNβ-Luc) expression (Fig. 4c). Conversely, we noted a decreased IFNβ expression at 24 h in UBE2J1-overexpressed HEK293T cells post DENV infection (Fig. 4d and e). However, the IFNβ was increased on 48 h after DENV infection with UBE2J1 overexpression (Fig. 4d and e). We hypothesized that this may be the secondary effect of the enhanced viral replication at late time point in those cells. These results suggest that UBE2J1 negatively regulates type one interferon signaling processes and suppresses early IFN production during virus infection.

Fig. 4
figure 4

UBE2J1 negatively regulates IRF3-mediated IFNβ signaling. a IFNβ mRNA expression in scramble shRNA (N.C.) or UBE2J1 shRNA transfected HEK293T cells after DENV infection. b Protein levels of IFNβ in scramble shRNA (N.C.) or UBE2J1 shRNA transfected HEK293T cells after DENV infection. c HEK293T cells were co-transfected with the IFNβ luciferase reporter, RIG-I-N (or vector), pRL-TK and UBE2J1 (or N.C.) shRNA plasmids. At 24 h after transfection, luciferase reporter assay was used to analysis of IFNβ promoter activity. d HEK293T cells were transfected with vector or UBE2J1 overexpression plasmids and infected with DENV. At 24 h or 48 h post infection, IFNβ mRNA expression was analyzed by qRT-PCR. e DENV induced IFNβ protein in UBE2J1 overexpressing or control HEK293T cells as quantified using ELISA. f Effect of overexpression of UBE2J1 on IFNβ reporter activation directed by RIG-I-N, MAVS, TRAF3, TBK1, IKKε, or IRF3-5D. Western blots were performed to confirm the overexpression of indicated proteins. g-i UBE2J1 suppressed DENV induced ISRE-promoter activity and ISG mRNA production. HEK293T cells were transfected with UBE2J1 (or N.C.) shRNA and then treated with DENV (or Mock) infection. At 24 h post infection, ISRE promoter activities were analyzed by luciferase assay (g) and ISG15 (h) and MxA (i) mRNA expression were measured by qRT-PCR. j Overexpression of UBE2J1 downregulated RIG-I-N, or IRF3-5D induced IRF3 promoter (IRF3-Luc) activity. k Western blots were used to confirm the overexpression of indicated proteins shown in data J. Results were expressed as the mean + SD. *p < 0.05 and ** p < 0.01 (t-test). Representative results from at least 3 independent experiments

Full size image

RIG-I, MAVS, TBK1, IKKε, and IRF3 participate in IFN production during RNA virus infection. Therefore, we investigated the action point of UBE2J1 by dissecting its suppressive effects on these transducer proteins. UBE2J1-overexpressing plasmids, together with one of the IFN pathway activators, RIG-I-N, MAVS, TRAF3, TBK1, IKKε or IRF3-5D, were co-transfected into HEK293T cells. The expression these individual constructs of IFN pathway molecules activates IFNβ-Luc reporter activity. UBE2J1 was found to significantly inhibit IFNβ-Luc activity induced by RIG-I-N, TRAF3 and IRF3-5D (Fig. 4f).

Accordingly, the ISRE promoter activations were also induced when silencing UBE2J1 (Fig. 4g). Meanwhile, the mRNA levels of typical interferon stimulated genes, ISG15 and MxA, were up-regulated and in consistent with the ISRE promoter activity (Fig. 4h and i).

To further validate whether UBE2J1 directly inhibits IRF3 activation, IRF3-specific luciferase activity was induced by coexpression of RIG-I-N or IRF3-5D. The IRF3 promoter activation (measured by an IRF3 specific reporter pIRF3-Luc (pRD (III–I)-Luc) [19]) was decreased in UBE2J1 overexpressed cells compared with controls (Fig. 4j and k), which implied that UBE2J1 could inhibit IRF3 transcriptional activity directly.

UBE2J1 inhibits IFN production by ubiquitination of IRF3

To confirm that UBE2J1 targets IRF3 to negatively regulate virus-triggered signaling, the protein levels of IFN pathway members were measured by western blot in DENV infected, UBE2J1 silenced and control HEK293T cells. Immunoblot analysis showed that the protein level of endogenous IRF3, but not RIG-I, MAVS, TRAF3, TBK1 or IKKε, was significantly increased in UBE2J1 silenced cells compared with controls (Fig. 5a). This suggests that UBE2J1 may target IRF3 for degradation.

Fig. 5
figure 5

UBE2J1 mainly promotes K48 -linked ubiquitination of IRF3. a HEK293T cells were transfected with plasmids of UBE2J1 shRNA (or N.C.) and then infected with DENV for 24 h. RIG-I, MAVS, TRAF3, TBK1, IKKε, and IRF3 protein levels were detected by immunoprecipitation with indicated primary antibodies. The increased IRF3 protein level was indicated by stars (**). (b-d) UBE2J1 interacted with IRF3 and facilitated IRF3 ubiquitination. HEK293T cells were transfected with Flag-IRF3, HA-Ub (b), (or HA-K48-Ub (c)/HA-K63-Ub (d)), along with UBE2J1-His or control plasmids for 24 h. Cells were then treated with MG132 for 6 h before harvesting the cells lysates. Distinct types of ubiquitinated IRF3 proteins were detected by immunoprecipitation and western blotting with indicated tag antibodies

Full size image

We next test the role of UBE2J1 in ubiquitination of IRF3. His-tagged UBE2J1 was co-immunoprecipitated with Flag-IRF3 by Flag agarose, suggesting that IRF3 interacts with UBE2J1 (Fig. 5b-d). Moreover, the ubiquitin (HA-Ub) chains that conjugated to immunoprecipitated IRF3, were significantly increased in presence of overexpressed UBE2J1 when compared with controls (Fig. 5b). To investigate the types of ubiquitination chains linked to IRF3, we transfected cells with HA tagged ubiquitin mutants K48 or K63, which has only one lysine in ubiquitin at position 48 or 63, respectively. Immunoprecipitation followed by western blots demonstrated that overexpression of UBE2J1 significantly increased K48-linked ubiquitination of IRF3 (Fig. 5c). The K63-linked ubiquitination was also slight increased but not as dramatic as that of K48 ubiquitination (Fig. 5d). Taken together, these findings suggest that UBE2J1 mainly promotes K48-linked ubiquitination of IRF3 and leads to the degradation of IRF3.

Discussion

In the last few years, ubiquitin modifications have been reported as important regulators of antiviral innate responses including the interferon signaling pathway. For example, TRIM25 mediated K63-ubiquitination of RIG-I is one of the first events following viral infection [6, 24]. Upon activation, RIG-I recruits the several E3s including TRAF6, TRAF2/5, and TRAF3 through the adaptor protein MAVS. Once TRAF6 and RIP1 are K63 polyubiquitinated, they recruit the TAK1 and IKK complexes. Then TAK1 phosphorylates and activates the IKK complex, activating IKKβ and lead to IκBα degradation [10, 25, 26]. K63-linked polyubiquitination of TRAF3 promotes IRF3 activation. Moreover, the activation of NF-κB and IRF3 can be triggered through K27-linked polyubiquitination of NEMO via TRIM23 [27]. On the other hand, K48-specific polyubiquitination trigger proteasomal degradation of signaling molecules in RIG-I pathway [28, 29]. For example, E3 RNF125 induces degradation of RIG-I, MDA5, and MAVS [30, 31]. E3 enzymes HOIL-1 L and HOIP mediate linear ubiquitination, in which the C-terminal carboxyl groups of ubiquitin is conjugated to the α-amino group of N-terminus of another ubiquitin, inhibit RIG-I signaling [32, 33].

Since E2 protein families are critical for determination the types and length of ubiquitin chains, we screened the function of 34 human E2 members on DENV infection. We have found that silencing UBE2J1, UBE2B and CDC34 significantly impaired DENV infection. While, silencing UBE2S, UBE2U, UBE2I and UBE2V1 significantly enhanced DENV infection (Fig. 1a). Among them, CDC34 and UBE2J1 are mainly responsible for K48 linked ubiquitination [15]. UBE2S mediates K11 linked ubiquitination [34, 35]. UBE2V1, formed a heterodimer with UBE2N, mediates K63 ubiquitination which are reported to be important in activation of RIG-I and NF-κB signaling [36]. UBE2I, also named as UBC9, are responsible for protein sumolytion [37]. Chiu M. et al. reported that UBC9 interacts with DENV-2 E protein; overexpression of UBC9 could reduce DENV infection in mammalian cells [38]. This is consistent with our result that silencing UBE2I causing an increased viral mRNA transcript copies in HEK293T cells (Fig. 1a). While, another study, using yeast two-hybrid assay, identified that UBE2I interacted with several DENV NS proteins; silencing UBE2I caused a significant decrease in the replication of a DENV replicon. [39]. In addition, Su C et al. suggested that silencing UBC9 (UBE2I) resulted in NS5 degradation [40]. Since the inconsistent conclusions are existed, further studies will be required to dissect the roles of UBE2I in DENV mRNA replication and protein modifications.

It is well known that UBE2J1 is involved in Endoplasmic Reticulum-Associated Protein Degradation (ERAD) process to degrade the incorrect folding proteins on ERs [41]. Two recent CRISPR/Cas9 screening studies suggested that ER-associated multi-protein complexes, N-linked glycosylation and ER associated degradation are required for flavivirus infectivity. UBE2J1 was also identified in their screenings as a pro-viral protein required for DENV and West Nile Virus infection [42, 43]. Our current study further suggested that UBE2J1 is responsible for ubiquitination of transcription factor IRF3, and mediates IRF3 degradation. In addition, IRF3 is also reported to be modified by UBC5 mediated K63-linked ubiquitination; but this modification is required for IRF3 activation, rather than degradation [44].

Since UBE2J1 mediated ERAD process may influence the stability of many proteins, we believed that IRF3 could just be one of the targets that modified by UBE2J1 during DENV infection. The modification of interferon pathway by UBE2J1 could be one possible mechanism for its pro-viral role in DENV infection. To further investigate the potential targets of UBE2J1 during DENV infection, an immunoprecipitation and protein Mass spectrum identification study was performed in DENV infected cells. Ubiquitin activating enzyme E1, several ubiquitin ligases E3s and proteins involved in protein translation (EIF4A2 and EIF4A2) or glycosylation (e.g. Triosephosphate isomerase) were identified that directly binding to UBE2J1 (data not shown). Further study will investigate the functions of UBE2J1 on these potential targets during DENV infection. Also, we will further characterize the roles of other UBE2s that identified in our screening and reveal the potential roles of different types of ubiquitination during RNA virus infection.

Conclusion

In conclusion, we reported that UBE2J1, one of ubiquitin E2 protein, could facilitate RNA virus replication. UBE2J1 mediates the ubiquitination and degradation of transcription factor IRF3, thereby negatively regulates type one IFN expression. This study could provide new evidences for the function of E2s and direct the development of new antiviral drugs against distinct E2 proteins.

Abbreviations

DENV:

Dengue virus

E2:

Ubiquitin-conjugating enzyme

IRF3-5D:

The constitutively active IRF3

RIG-I-N:

The active caspase recruitment domain (CARD) containing form of RIG-I

References

  1. Guo C, Zhou Z, Wen Z, Liu Y, Zeng C, Xiao D, Ou M, Han Y, Huang S, Liu D, et al. Global epidemiology of dengue outbreaks in 1990-2015: a systematic review and meta-analysis. Front Cell Infect Microbiol. 2017;7:317.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Pang EL, Loh HS. Towards development of a universal dengue vaccine - how close are we? Asian Pac J Trop Med. 2017;10:220–8.

    Article  PubMed  CAS  Google Scholar 

  3. Malmgaard L. Induction and regulation of IFNs during viral infections. J Interf Cytokine Res. 2004;24:439–54.

    Article  CAS  Google Scholar 

  4. Kunzi MS, Pitha PM. Interferon targeted genes in host defense. Autoimmunity. 2003;36:457–61.

    Article  PubMed  CAS  Google Scholar 

  5. Schindler C, Plumlee C. Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol. 2008;19:311–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Davis ME, Gack MU. Ubiquitination in the antiviral immune response. Virology. 2015;479-480:52–65.

    Article  PubMed  CAS  Google Scholar 

  7. Heaton SM, Borg NA, Dixit VM. Ubiquitin in the activation and attenuation of innate antiviral immunity. J Exp Med. 2016;213:1–13.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Wang L, Zhao W, Zhang M, Wang P, Zhao K, Zhao X, Yang S, Gao C. USP4 positively regulates RIG-I-mediated antiviral response through deubiquitination and stabilization of RIG-I. J Virol. 2013;87:4507–15.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Ye Y, Rape M. Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol Cell Biol. 2009;10:755–64.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Chen ZJ. Ubiquitination in signaling to and activation of IKK. Immunol Rev. 2012;246:95–106.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Maelfait J, Beyaert R. Emerging role of ubiquitination in antiviral RIG-I signaling. Microbiol Mol Biol Rev. 2012;76:33–45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Komander D, Rape M. The ubiquitin code. Annu Rev Biochem. 2012;81:203–29.

    Article  PubMed  CAS  Google Scholar 

  13. David Y, Ziv T, Admon A, Navon A. The E2 ubiquitin-conjugating enzymes direct polyubiquitination to preferred lysines. J Biol Chem. 2010;285:8595–604.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Eldridge MJ, Sanchez-Garrido J, Hoben GF, Goddard PJ, Shenoy AR. The atypical ubiquitin E2 Conjugase UBE2L3 is an indirect Caspase-1 target and controls IL-1beta secretion by Inflammasomes. Cell Rep. 2017;18:1285–97.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Suryadinata R, Holien JK, Yang G, Parker MW, Papaleo E, Sarcevic B. Molecular and structural insight into lysine selection on substrate and ubiquitin lysine 48 by the ubiquitin-conjugating enzyme Cdc34. Cell Cycle. 2013;12:1732–44.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Zhou W, Xu J, Li H, Xu M, Chen ZJ, Wei W, Pan Z, Sun Y. Neddylation E2 UBE2F promotes the survival of lung Cancer cells by activating CRL5 to degrade NOXA via the K11 linkage. Clin Cancer Res. 2017;23:1104–16.

    Article  PubMed  CAS  Google Scholar 

  17. Pichler A, Fatouros C, Lee H, Eisenhardt N. SUMO conjugation - a mechanistic view. Biomol Concepts. 2017;8:13–36.

    Article  PubMed  CAS  Google Scholar 

  18. Hochstrasser M. Origin and function of ubiquitin-like proteins. Nature. 2009;458:422–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Zhao T, Yang L, Sun Q, Arguello M, Ballard DW, Hiscott J, Lin R. The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways. Nat Immunol. 2007;8:592–600.

    Article  PubMed  CAS  Google Scholar 

  20. Li J, Hu DM, Ding XX, Chen Y, Pan YX, Qiu LW, Che XY. Enzyme-linked immunosorbent assay-format tissue culture infectious dose-50 test for titrating dengue virus. PLoS One. 2011;6:e22553.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Wu S, He L, Li Y, Wang T, Feng L, Jiang L, Zhang P, Huang X. miR-146a facilitates replication of dengue virus by dampening interferon induction by targeting TRAF6. J Inf Secur. 2013;67:329–41.

    Google Scholar 

  22. Kalbfuss B, Knochlein A, Krober T, Reichl U. Monitoring influenza virus content in vaccine production: precise assays for the quantitation of hemagglutination and neuraminidase activity. Biologicals. 2008;36:145–61.

    Article  PubMed  CAS  Google Scholar 

  23. Li G, Feng T, Pan W, Shi X, Dai J. DEAD-box RNA helicase DDX3X inhibits DENV replication via regulating type one interferon pathway. Biochem Biophys Res Commun. 2015;456:327–32.

    Article  PubMed  CAS  Google Scholar 

  24. Munir M. TRIM proteins: another class of viral victims. Sci Signal. 2010;3:jc2.

    Article  PubMed  CAS  Google Scholar 

  25. Emmerich CH, Ordureau A, Strickson S, Arthur JS, Pedrioli PG, Komander D, Cohen P. Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains. Proc Natl Acad Sci U S A. 2013;110:15247–52.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 2001;412:346–51.

    Article  PubMed  CAS  Google Scholar 

  27. Arimoto K, Funami K, Saeki Y, Tanaka K, Okawa K, Takeuchi O, Akira S, Murakami Y, Shimotohno K. Polyubiquitin conjugation to NEMO by triparite motif protein 23 (TRIM23) is critical in antiviral defense. Proc Natl Acad Sci U S A. 2010;107:15856–61.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Hu MM, Liao CY, Yang Q, Xie XQ, Shu HB. Innate immunity to RNA virus is regulated by temporal and reversible sumoylation of RIG-I and MDA5. J Exp Med. 2017;214:973–89.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Zhao X, Zhu H, Yu J, Li H, Ge J, Chen W. c-Cbl-mediated ubiquitination of IRF3 negatively regulates IFN-beta production and cellular antiviral response. Cell Signal. 2016;28:1683–93.

    Article  PubMed  CAS  Google Scholar 

  30. Britto AM, Amoedo ND, Pezzuto P, Afonso AO, Martinez AM, Silveira J, Sion FS, Machado ES, Soares MA, Giannini AL. Expression levels of the innate response gene RIG-I and its regulators RNF125 and TRIM25 in HIV-1-infected adult and pediatric individuals. AIDS. 2013;27:1879–85.

    Article  PubMed  CAS  Google Scholar 

  31. Oshiumi H, Matsumoto M, Seya T. Ubiquitin-mediated modulation of the cytoplasmic viral RNA sensor RIG-I. J Biochem. 2012;151:5–11.

    Article  PubMed  CAS  Google Scholar 

  32. Rittinger K, Ikeda F. Linear ubiquitin chains: enzymes, mechanisms and biology. Open Biol. 2017;7

  33. Bowman J, Rodgers MA, Shi M, Amatya R, Hostager B, Iwai K, Gao SJ, Jung JU. Posttranslational modification of HOIP blocks toll-like receptor 4-mediated linear-ubiquitin-chain formation. MBio. 2015;6:e01777–15.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Min M, Mevissen TE, De Luca M, Komander D, Lindon C. Efficient APC/C substrate degradation in cells undergoing mitotic exit depends on K11 ubiquitin linkages. Mol Biol Cell. 2015;26:4325–32.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Kuang P, Tan M, Zhou W, Zhang Q, Sun Y. SAG/RBX2 E3 ligase complexes with UBCH10 and UBE2S E2s to ubiquitylate beta-TrCP1 via K11-linkage for degradation. Sci Rep. 2016;6:37441.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Shi Y, Yuan B, Zhu W, Zhang R, Li L, Hao X, Chen S, Hou F. Ube2D3 and Ube2N are essential for RIG-I-mediated MAVS aggregation in antiviral innate immunity. Nat Commun. 2017;8:15138.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Tahmasebi S, Ghorbani M, Savage P, Gocevski G, Yang XJ. The SUMO conjugating enzyme Ubc9 is required for inducing and maintaining stem cell pluripotency. Stem Cells. 2014;32:1012–20.

    Article  PubMed  CAS  Google Scholar 

  38. Chiu MW, Shih HM, Yang TH, Yang YL. The type 2 dengue virus envelope protein interacts with small ubiquitin-like modifier-1 (SUMO-1) conjugating enzyme 9 (Ubc9). J Biomed Sci. 2007;14:429–44.

    Article  PubMed  CAS  Google Scholar 

  39. Khadka S, Vangeloff AD, Zhang C, Siddavatam P, Heaton NS, Wang L, Sengupta R, Sahasrabudhe S, Randall G, Gribskov M, et al. A physical interaction network of dengue virus and human proteins. Mol Cell Proteomics. 2011;10:M111 012187.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Su CI, Tseng CH, Yu CY, Lai MMC. SUMO modification stabilizes dengue virus nonstructural protein 5 to support virus replication. J Virol. 2016;90:4308–19.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Lemus L, Goder V. Regulation of endoplasmic reticulum-associated protein degradation (ERAD) by ubiquitin. Cells. 2014;3:824–47.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Marceau CD, Puschnik AS, Majzoub K, Ooi YS, Brewer SM, Fuchs G, Swaminathan K, Mata MA, Elias JE, Sarnow P, Carette JE. Genetic dissection of Flaviviridae host factors through genome-scale CRISPR screens. Nature. 2016;535:159–63.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Zhang R, Miner JJ, Gorman MJ, Rausch K, Ramage H, White JP, Zuiani A, Zhang P, Fernandez E, Zhang Q, et al. A CRISPR screen defines a signal peptide processing pathway required by flaviviruses. Nature. 2016;535:164–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Zeng W, Xu M, Liu S, Sun L, Chen ZJ. Key role of Ubc5 and lysine-63 polyubiquitination in viral activation of IRF3. Mol Cell. 2009;36:315–25.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Availability of data and material

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Funding

This work was supported by the National Natural Science Foundation of China (31770933, 81471571 and 31500700), Natural Science Foundation of Colleges in Jiangsu Province (17KJA310005), Suzhou Science and Technology Development Project (SNG201607, SNG2017049), the Priority Academic Program Development of Jiangsu Higher Education Institutions, and Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT).

Author information

Authors and Affiliations

  1. Institute of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, 199 Ren-ai Road, Suzhou, 215123, People’s Republic of China

    Tingting Feng, Lei Deng, Xiaochuan Lu, Wen Pan & Jianfeng Dai

  2. Key Laboratory of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University, Shanghai Institute of Planned Parenthood Research, Shanghai, 200032, People’s Republic of China

    Qihan Wu & Jianfeng Dai

Authors
  1. Tingting Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lei Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaochuan Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wen Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qihan Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jianfeng Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

T.F.,Q.W. and J.D. designed the experiments and prepared the manuscript. T.F., L.D., X.L., and W.P. performed the experiments and analyzed the data. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Qihan Wu or Jianfeng Dai.

Ethics declarations

Ethics approval and consent to participate

PBMC (human Peripheral Blood Mononuclear Cells) were obtained from BeNa Culture Collection (Bejing, China). Samples were anonymized and the projects using of human biological specimens were approved by an institutional review board (IRB) of Soochow University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional file

Additional files 1

Oligo-primer sequences for qRT-PCR Assay (DOCX 16 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Feng, T., Deng, L., Lu, X. et al. Ubiquitin-conjugating enzyme UBE2J1 negatively modulates interferon pathway and promotes RNA virus infection. Virol J 15, 132 (2018). https://doi.org/10.1186/s12985-018-1040-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12985-018-1040-5

Keywords

  • UBE2J1
  • Dengue virus
  • Interferons
  • IRF3
  • K48 ubiquitination

Virology Journal

ISSN: 1743-422X